全文获取类型
收费全文 | 1672篇 |
免费 | 130篇 |
国内免费 | 8篇 |
学科分类
医药卫生 | 1810篇 |
出版年
2023年 | 14篇 |
2022年 | 26篇 |
2021年 | 111篇 |
2020年 | 63篇 |
2019年 | 109篇 |
2018年 | 111篇 |
2017年 | 54篇 |
2016年 | 62篇 |
2015年 | 61篇 |
2014年 | 97篇 |
2013年 | 88篇 |
2012年 | 161篇 |
2011年 | 150篇 |
2010年 | 64篇 |
2009年 | 61篇 |
2008年 | 77篇 |
2007年 | 90篇 |
2006年 | 74篇 |
2005年 | 69篇 |
2004年 | 50篇 |
2003年 | 43篇 |
2002年 | 37篇 |
2001年 | 14篇 |
2000年 | 7篇 |
1999年 | 6篇 |
1998年 | 4篇 |
1997年 | 3篇 |
1996年 | 4篇 |
1995年 | 6篇 |
1994年 | 2篇 |
1993年 | 3篇 |
1992年 | 5篇 |
1991年 | 6篇 |
1990年 | 3篇 |
1989年 | 3篇 |
1988年 | 4篇 |
1987年 | 7篇 |
1986年 | 3篇 |
1985年 | 2篇 |
1983年 | 8篇 |
1982年 | 6篇 |
1981年 | 5篇 |
1979年 | 5篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1976年 | 6篇 |
1975年 | 6篇 |
1974年 | 6篇 |
1973年 | 3篇 |
1972年 | 2篇 |
排序方式: 共有1810条查询结果,搜索用时 31 毫秒
981.
Maxime Duval Audrey Mirand Olivier Lesens Jacques-Olivier Bay Denis Caillaud Denis Gallot Alexandre Lautrette Sylvie Montcouquiol Jeannot Schmidt Carole Egron Gwendoline Jugie Maxime Bisseux Christine Archimbaud Cline Lambert Ccile Henquell Jean-Luc Bailly 《Viruses》2021,13(8)
Enterovirus D68 (EV-D68) has emerged as an agent of epidemic respiratory illness and acute flaccid myelitis in the paediatric population but data are lacking in adult patients. We performed a 4.5-year single-centre retrospective study of all patients who tested positive for EV-D68 and analysed full-length EV-D68 genomes of the predominant clades B3 and D1. Between 1 June 2014, and 31 December 2018, 73 of the 11,365 patients investigated for respiratory pathogens tested positive for EV-D68, of whom 20 (27%) were adults (median age 53.7 years [IQR 34.0–65.7]) and 53 (73%) were children (median age 1.9 years [IQR 0.2–4.0]). The proportion of adults increased from 12% in 2014 to 48% in 2018 (p = 0.01). All adults had an underlying comorbidity factor, including chronic lung disease in 12 (60%), diabetes mellitus in six (30%), and chronic heart disease in five (25%). Clade D1 infected a higher proportion of adults than clades B3 and B2 (p = 0.001). Clade D1 was more divergent than clade B3: 5 of 19 amino acid changes in the capsid proteins were located in putative antigenic sites. Adult patients with underlying conditions are more likely to present with severe complications associated with EV-D68, notably the emergent clade D1. 相似文献
982.
983.
Latifa Tahiri Sandra Guignard Patricia Pinto Muriel Duclos Maxime Dougados 《Joint, bone, spine : revue du rhumatisme》2009,76(6):715-717
Cardiac involvement is a complication of end stage polymyositis with left heart insufficiency reported to be the most frequent manifestation. We here describe an unusual clinical presentation of antisynthetases syndrome, beginning with right-sided cardiomyopathy associated with right heart failure. A 26 year-old Caucasian male experienced a 6-month clinical course of polyarthritis, fever, sweats, and myalgia. Laboratory studies showed elevated C reactive protein, elevated sedimentation rate, and myolysis associated with anti SSA and anti JO1 antibodies. Electromyography showed a myopathic pattern. Muscle biopsy confirmed the diagnosis of polymyositis. Chest X ray, chest scan, and cardiac echography were normal. One week after hospital admission, the patient developed acute right heart insufficiency, and magnetic resonance imaging showed a right ventricular myocarditis with myocardial inflammatory thickening. Treatment with corticosteroids rapidly improved both symptoms and biological abnormalities. 相似文献
984.
Crozet MD Botta C Gasquet M Curti C Rémusat V Hutter S Chapelle O Azas N De Méo M Vanelle P 《European journal of medicinal chemistry》2009,44(2):653-659
To improve the antiparasitic pharmacophore, 20 5-nitroimidazoles bearing an arylsulfonylmethyl group were prepared from commercial imidazoles. The antiparasitic activity of these molecules was assessed against Trichomonas vaginalis, the in vitro cytotoxicity was evaluated on human monocytes and the mutagenicity was determined by the Salmonella mutagenicity assay. All IC(50) on T. vaginalis were below the one of metronidazole. The determination of the specificity indexes (SIs), defined as the ratios of the cytotoxic activity and the antitrichomonas activity, indicated that 11 derivatives had a SI over the one of metronidazole. Molecules, bearing an additional methyl group on the 2-position, showed a lower mutagenicity than metronidazole. Moreover, three derivatives were characterized by a low mutagenicity and an efficient antitrichomonas activity. 相似文献
985.
Jamal A. Alhashemi Maurizio Cecconi Giorgio della Rocca Maxime Cannesson Christoph K. Hofer 《Current heart failure reports》2010,7(3):116-124
Cardiac output monitoring in the cardiac surgery patient is standard practice that is traditionally performed using the pulmonary
artery catheter. However, over the past 20 years, the value of pulmonary artery catheters has been challenged, with some authors
suggesting that its use might be not only unnecessary but also harmful. New minimally invasive devices that measure cardiac
output have become available. In this paper, we review their operative principles, limitations, and utility in an integrated
approach that could potentially change patients’ outcome. However, it is now clear that it is how the monitor is used (ie,
the protocol or therapy associated with its use, or its lack thereof), and not the monitor per se, that should be questioned
when a patient’s outcome is being evaluated. 相似文献
986.
987.
Gilles Allali MD PhD Bruno Dubois MD PhD Frederic Assal MD Elise Lallart MS Leonardo C. de Souza MD MS Maxime Bertoux MS Cédric Annweiler MD MS Francois R. Herrmann MD MPH Richard Levy MD PhD Olivier Beauchet MD PhD 《Movement disorders》2010,25(6):731-737
The main diagnostic criteria of the behavioural variant of frontotemporal degeneration (bvFTD) include neurobehavioral and dysexecutive syndromes, but not specific gait characteristics although strong relationship between gait and prefrontal functions are increasingly recognized. Accordingly, we tested the hypothesis that patients with bvFTD would have more gait changes than older healthy controls and demented patients with Alzheimer's disease (AD). Sixty subjects were included in the study: 19 with bvFTD, 19 with AD and 22 healthy controls. Mean values and coefficients of variation (CV) of stride time while just walking (i.e., single tasking) and while walking with backward counting (i.e., dual tasking) were measured using the SMTEC®‐footswitch system. Stride time, mean value, and CV were significantly increased in both patient groups compared with healthy controls during single task or walking alone (P < 0.001) and during dual tasking (P < 0.001). After adjusting for age, Mini‐mental examination, psychoactive drugs, gender, and history of previous fall, only the patients with bvFTD group was associated with an increase of CV of stride time during single walking (P < 0.001) and dual tasking (P < 0.001). These data suggest that gait instability during single and dual tasking could represent a supportive argument for bvFTD. In clinical practice, such a diagnosis should be at least considered in any demented patient with gait instability. © 2010 Movement Disorder Society 相似文献
988.
989.
Reorganization and plasticity after spinal cord injury have been recently shown to take place in sublesional neuronal networks, but the possibility of strain-dependent changes at that level has never been explored. The authors studied the spontaneous return of hindlimb movement in low-thoracic spinal cord transected (Tx) mice from 3 commonly used strains. Without intervention, most CD1, C57BL/6, and BALB/c mice displayed some hindlimb movement recovery after Tx. Although all assessment methods unanimously reported that CD1 displayed higher recovery levels than did the C57BL/6 and BALB/c, higher scores were generally found with the Antri-Orsal-Barthe (M. Antri, D. Orsal, & J. Y. Barthe, 2002) and the Average Combined Score (P. A. Guertin, 2005a) methods. Such spontaneous recovery in low-thoracic Tx mice is likely the result of neuronal plasticity at the lumbosacral spinal cord level, suggesting that these sublesional changes are strain dependent. 相似文献
990.
Bingham CO Buckland-Wright JC Garnero P Cohen SB Dougados M Adami S Clauw DJ Spector TD Pelletier JP Raynauld JP Strand V Simon LS Meyer JM Cline GA Beary JF 《Arthritis and rheumatism》2006,54(11):3494-3507
OBJECTIVE: Bisphosphonates have slowed the progression of osteoarthritis (OA) in animal models and have decreased pain in states of high bone turnover. The Knee OA Structural Arthritis (KOSTAR) study, which is the largest study to date investigating a potential structure-modifying OA drug, tested the efficacy of risedronate in providing symptom relief and slowing disease progression in patients with knee OA. METHODS: The study group comprised 2,483 patients with medial compartment knee OA and 2-4 mm of joint space width (JSW), as determined using fluoroscopically positioned, semiflexed-view radiography. Patients were enrolled in 2 parallel 2-year studies in North America and the European Union. These studies evaluated the efficacy of risedronate at dosages of 5 mg/day, 15 mg/day, 35 mg/week (in Europe), and 50 mg/week (in North America) compared with placebo in reducing signs and symptoms, as measured by the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index and patient global assessment (PGA) scores, and in slowing radiographic progression. RESULTS: A reduction of approximately 20% in signs and symptoms, as measured by WOMAC subscales and PGA scores, was observed in all groups, with no treatment effect of risedronate demonstrated. Risedronate did not significantly reduce radiographic progression as measured by decreased JSW or using a dichotomous definition of progression (joint space loss of >or=0.6 mm). Thirteen percent of patients receiving placebo demonstrated significant disease progression over 2 years. A dose-dependent reduction in the level of C-terminal crosslinking telopeptide of type II collagen, a cartilage degradation marker associated with progressive OA, was seen in patients who received risedronate. No increase in the number of adverse events was demonstrated for risedronate compared with placebo. CONCLUSION: Although risedronate (compared with placebo) did not improve signs or symptoms of OA, nor did it alter progression of OA, a reduction in the level of a marker of cartilage degradation was observed. A sustained clinically relevant improvement in signs and symptoms was observed in all treatment and placebo groups. 相似文献